Related Articles
Safety and continuity of second‑ and third‑line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer
Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer
Paclitaxel for relapsed small‑cell lung cancer patients with idiopathic interstitial pneumonias
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens